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Objectives: HLA-B*5701 is highly associated with ABC HSR in Whites. However, variable sensitivities 
are reported across studies and races where clinical data alone defined ABC HSR. Because accurate 
identification of phenotype is critical for determining sensitivity, this study estimates the sensitivity 
of HLA-B*5701 in Whites and Blacks using skin patch testing (SPT) to supplement HSR diagnosis.  
Methods: Subjects who had clinically-suspected ABC HSR were retrospectively identified and then 
tested for HLA-B*5701 and underwent ABC SPT (Study ABC107442, clinicaltrials.gov identifier: 
NCT00373945). Cases were defined as (1) All ABC HSR regardless of SPT results and (2) ABC HSR with 
a positive SPT result. Controls were subjects who tolerated ABC for ³12 weeks without HSR. 
  
Results:  
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42  127  202  5  48  206 
HLA-
B*5701+, n 
42  56  8  5  10  2 
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0  71  194  0  38  204 
Sensitivity 
(95% CI) 
1.0 (0.92, 1.0) 
0.44 (0.35, 
0.53) 
-  1.0 (0.48, 1.0) 
0.21 (0.10, 
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(95% CI) 
-  - 
0.96 (0.92, 
0.98) 
-  - 
0.99 (0.97, 
1.00) 
1Includes SPT+ and SPT- cases (3 had no SPT result). Among 82 SPT- cases, 14 were HLA-B*5701+. 
2Includes SPT+ and SPT- cases. Among 43 SPT- cases, 5 were HLA-B*5701+.  
 
Conclusions: In these preliminary results, the sensitivity of HLA-B*5701 for SPT+ HSR is 100% in both 
Whites and Blacks. The sensitivity of HLA-B*5701 was reduced when HSR was defined by clinical 
diagnosis alone. These data suggest that prospective HLA-B*5701 screening may reduce ABC HSR 
rates in Whites and Blacks. Not all HLA-B*5701+ cases were SPT+. HLA-B*5701 screening may 
augment clinical management of HSR but must never substitute for clinical vigilance. To complement 
these results, a large prospective study (PREDICT-1) evaluating the clinical utility of HLA-B*5701 
screening on ABC HSR has been completed. 